
Talazoparib tosylate
CAS No. 1373431-65-2
Talazoparib tosylate( —— )
Catalog No. M33505 CAS No. 1373431-65-2
Talazoparib tosylate is a novel and potent PARP1/2 (n IC50: 0.57 nM for PARP1).
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameTalazoparib tosylate
-
NoteResearch use only, not for human use.
-
Brief DescriptionTalazoparib tosylate is a novel and potent PARP1/2 (n IC50: 0.57 nM for PARP1).
-
DescriptionTalazoparib tosylate (BMN 673ts) is a novel, potent and orally available PARP1/2 inhibitor with an IC50 of 0.57 nM for PARP1.
-
In VitroTalazoparib is a potent PARP1/2 inhibitor (PARP1 IC50=0.57 nM), it has no effect on PARG activity at concentrations up to 1 μM. Talazoparib binds to PARP1 with a dissociation constant (KD) of 0.29 nM. Talazoparib inhibits PARP1 and -2 to a similar extent, with Kis of 1.20 and 0.85 nM, respectively. Talazoparib selectively targets tumor cells with BRCA1, BRCA2, or PTEN gene defects with 20- to more than 200-fold greater potency than existing PARP1/2 inhibitors. Talazoparib targets tumor cells with homologous recombination gene defects. Tumor models that are either BRCA1-deficient (MX-1 and SUM149) or BRCA2-deficient (Capan-1) are profoundly sensitive to Talazoparib. Talazoparib induces nuclear γ-H2AX foci at concentrations as low as 100 pM.
-
In VivoTalazoparib is readily orally bioavailable, with more than 40% absolute oral bioavailability in rats when dosed in carboxylmethyl cellulose. Oral administration of Talazoparib elicits remarkable antitumor activity; xenografted tumors that carry defects in DNA repair due to BRCA mutations or PTEN deficiency are profoundly sensitive to oral Talazoparib treatment at well-tolerated doses in mice. Synergistic or additive antitumor effects are also found when Talazoparib is combined with temozolomide, SN38, or platinum drugs.
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetPARP
-
RecptorPARP
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1373431-65-2
-
Formula Weight552.55
-
Molecular FormulaC26H22F2N6O4S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : ≥ 108 mg/mL (195.46 mM) H2O : < 0.1 mg/mL (insoluble)
-
SMILESCc1ccc(cc1)S(O)(=O)=O.Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Shen Y, et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res. 2013 Sep 15;19(18):5003-15.?
molnova catalog



related products
-
UNBS-5162
UNBS-5162 is a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers.
-
4-amino-1,8-Naphthal...
4-amino-1,8-Naphthalimide (4-ANI) is a PARP inhibitor with IC50 of 180 nM.
-
NVP-BVU972
NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.